HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.
- DOI
- 10.1016/j.xcrm.2026.102789
- Published
- 2026 May 19
- Container
- Cell reports. Medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.xcrm.2026.102789,
title = {HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.},
author = {Braun DA and Noel MS and Moy RH and Demel K and Gutierrez M and Sharma S and Hussain A and Gadgeel S and Peguero J and Choueiri TK and Emamekhoo H and Van Tine B and Balaraman R and Elliott G and Nath S and Daigle SR and Kumar P and Scheuber A and Sommerhalder D},
year = {2026},
journal = {Cell reports. Medicine},
doi = {10.1016/j.xcrm.2026.102789},
url = {https://doi.org/10.1016/j.xcrm.2026.102789}
}RIS
TY - JOUR TI - HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results. AU - Braun DA AU - Noel MS AU - Moy RH AU - Demel K AU - Gutierrez M AU - Sharma S AU - Hussain A AU - Gadgeel S AU - Peguero J AU - Choueiri TK AU - Emamekhoo H AU - Van Tine B AU - Balaraman R AU - Elliott G AU - Nath S AU - Daigle SR AU - Kumar P AU - Scheuber A AU - Sommerhalder D PY - 2026 JO - Cell reports. Medicine DO - 10.1016/j.xcrm.2026.102789 UR - https://doi.org/10.1016/j.xcrm.2026.102789 ER -
APA
DA, B., MS, N., RH, M., K, D., M, G., S, S., A, H., S, G., J, P., TK, C., H, E., B, V. T., R, B., G, E., S, N., SR, D., P, K., A, S., & D, S. (2026). HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.. Cell reports. Medicine. https://doi.org/10.1016/j.xcrm.2026.102789
Source records
- pubmed · retrieved 2026-09-26T17:38:14.467Z